This website uses cookies and similar technologies (hereinafter collectively referred to as ‘cookies’). We may use cookies for the following purposes:
With the buttons below, you can choose which cookies you wish to accept. On our cookie statement page, you can manage your cookie preferences. You can always withdraw your consent for cookies by making different choices there. For more information about cookies, please refer to our cookie statement.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen [alumnus RSM MScBA] to senior vice president and chief financial officer.
Read the article: https://www.placera.se/placera/pressmeddelanden/2024/04/09/xencor-xencor-appoints-bart-cornelissen-as-chief-financial-officer.html